[go: up one dir, main page]

PE20011266A1 - Derivados de 1,4-diazepan-2,5-diona - Google Patents

Derivados de 1,4-diazepan-2,5-diona

Info

Publication number
PE20011266A1
PE20011266A1 PE2001000458A PE2001000458A PE20011266A1 PE 20011266 A1 PE20011266 A1 PE 20011266A1 PE 2001000458 A PE2001000458 A PE 2001000458A PE 2001000458 A PE2001000458 A PE 2001000458A PE 20011266 A1 PE20011266 A1 PE 20011266A1
Authority
PE
Peru
Prior art keywords
diona
diazepan
derivatives
heteroaryl
benzyl
Prior art date
Application number
PE2001000458A
Other languages
English (en)
Inventor
Guido Galley
Reinhard Heck
Annick Goergler
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20011266A1 publication Critical patent/PE20011266A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,4-DIAZEPAN-2,5-DIONA DONDE R1 Y R2 SON ARILO, HETEROARILO CON HALOGENO, CF3, ALCOXILO, ALQUILO; R3 ES H, ALQUILO , -(CH2)nN(R)2, -(CH2)n-HETEROARILO, -(CH2)n-HETEROCICLO, ENTRE OTROS; R4 ES =O, =N(CH2)nCH3, =N(CH2)nN(R2); R3 Y R4 JUNTO A N, C FORMAN EL GRUPO -CR5=N-N=; R5 ES H, -(CH2)nN(R)2, -(CH2)n-HETEROARILO, (CH2)n-HETEROCICLO, ENTRE OTROS; R ES H, ALQUILO; n ES 0-3. SON COMPUESTOS PREFERIDOS (3S)-1-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-3-(3,4-DICLOROBENCIL)-[1,4]DIAZEPAN-2,5-DIONA, (3S)-3-(3,4-DICLORO-BENCIL)-1-(2-METOXI-NAFTALEN-1-IL-METIL)-[1,4]DIAZEPAN-2,5-DIONA, (3S)-3-(3,4-DICLORO-BENCIL)-1-(2-METIL-NAFTALEN-1-IL-METIL)-[1,4]DIAZEPAN-2,5-DIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPUESTOS INTERMEDIOS. LOS DERIVADOS DE 1,4-DIAZEPAN-2,5-DIONA SON ANTAGONISTAS DEL RECEPTOR DE LA NEUROQUININA 1 (NK-1) Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDADES INFLAMATORIAS TAL COMO MIGRANA, ARTRITIS REUMATOIDE, ASMA, PARKINSON
PE2001000458A 2000-05-25 2001-05-21 Derivados de 1,4-diazepan-2,5-diona PE20011266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00111249 2000-05-25

Publications (1)

Publication Number Publication Date
PE20011266A1 true PE20011266A1 (es) 2001-12-14

Family

ID=8168838

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000458A PE20011266A1 (es) 2000-05-25 2001-05-21 Derivados de 1,4-diazepan-2,5-diona

Country Status (18)

Country Link
US (1) US6452001B2 (es)
EP (1) EP1296961B1 (es)
JP (1) JP4060596B2 (es)
KR (1) KR100526696B1 (es)
CN (1) CN1178923C (es)
AR (1) AR028607A1 (es)
AT (1) ATE353881T1 (es)
AU (2) AU2001281778B2 (es)
BR (1) BR0111062A (es)
CA (1) CA2409842C (es)
DE (1) DE60126614T2 (es)
DK (1) DK1296961T3 (es)
ES (1) ES2280392T3 (es)
MX (1) MXPA02011464A (es)
PE (1) PE20011266A1 (es)
PT (1) PT1296961E (es)
WO (1) WO2001090083A1 (es)
ZA (1) ZA200208940B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
JP5118648B2 (ja) * 2005-12-29 2013-01-16 イミュファルマ・フランス・エスアー 疾患の処置および予防のための組成物および方法
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
WO2007074171A1 (en) * 2005-12-29 2007-07-05 Immupharma France Sa Aza heterocyclics for the treatment of malaria or aids
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
JP2009522234A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー ホスホリパーゼａ２を阻害する組成物および方法
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
KR101044833B1 (ko) * 2010-02-10 2011-06-28 (주)혜성나노텍 무차광 온실 보온커텐 종형 개폐장치
CN103951624B (zh) * 2010-08-26 2019-04-16 兴和株式会社 1,4-二氮杂环庚烷衍生物或其盐的制造方法
US8460460B2 (en) 2011-06-24 2013-06-11 Construction Research & Technology Gmbh Cementitious composition and admixture
CN108358893A (zh) * 2018-02-10 2018-08-03 安徽唯诗杨信息科技有限公司 一种一锅法合成四氢化苯并-[1,4]-二氮杂环庚烷衍生物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022765A (en) 1975-01-06 1977-05-10 E. R. Squibb & Sons, Inc. Triazolo[4,3-d][1,4]benzodiazepine-6-ones
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
WO1995018124A1 (en) 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
JP2003534332A (ja) 2003-11-18
KR20030003759A (ko) 2003-01-10
CN1178923C (zh) 2004-12-08
DE60126614T2 (de) 2007-11-22
US6452001B2 (en) 2002-09-17
AR028607A1 (es) 2003-05-14
WO2001090083A1 (en) 2001-11-29
AU2001281778B2 (en) 2005-06-02
EP1296961A1 (en) 2003-04-02
EP1296961B1 (en) 2007-02-14
CN1430611A (zh) 2003-07-16
ATE353881T1 (de) 2007-03-15
JP4060596B2 (ja) 2008-03-12
US20020010174A1 (en) 2002-01-24
AU8177801A (en) 2001-12-03
MXPA02011464A (es) 2003-04-25
ES2280392T3 (es) 2007-09-16
ZA200208940B (en) 2004-02-04
CA2409842A1 (en) 2001-11-29
BR0111062A (pt) 2003-06-10
PT1296961E (pt) 2007-05-31
DK1296961T3 (da) 2007-06-04
CA2409842C (en) 2008-07-29
KR100526696B1 (ko) 2005-11-08
DE60126614D1 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
PE20011266A1 (es) Derivados de 1,4-diazepan-2,5-diona
EA200600315A1 (ru) Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
PE20021041A1 (es) DERIVADOS DE DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-0NA COMO ANTAGONISTAS II mGLUR2
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20000337A1 (es) Pirazolpirimidinas y pirazoltriazinas
PE20020103A1 (es) Derivados de 1-sulfonil-pirrolidina
PE20041061A1 (es) Imidazol-4-il-etinil-piridina
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20011325A1 (es) Heterociclilalquilaminas como antagonistas de los receptores muscarinicos
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20091243A1 (es) Compuesto heterociclico fusionado
PE75199A1 (es) Derivado de quinolina util como antagonista de neuroquinina
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
ATE7598T1 (de) Einen halogen enthaltenden substituenten umfassende 2-alkoxycarbonylaminobenzimidazole, ihre herstellung und ihre verwendung als parasitizide.
PE20010153A1 (es) Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina
PE20061351A1 (es) COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
ATE263150T1 (de) Il-8 rezeptor antagonisten
AR070796A1 (es) Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed